| 产品描述: | SCO-267 is an allosteric GPR40 full agonist. SCO-267 can be used for the research of chronic diseases including diabetes[1]. |
| 体外研究: |
SCO-267 (1 or 10 mg/kg; p.o.) improves insulin sensitivity and exerts sustained glucose-lowering effect[1]. |
| 体内研究: |
SCO-267 (CHO cells) activates the Gαq, Gαs, and Gα12/13 pathways and β-Arrestin Recruitment. SCO-267 is allosteric with fasiglifam and an endogenous ligand[1]. |
| 参考文献: |
1. Koyama R, et al. Chronic Exposure to SCO-267, an Allosteric GPR40 Full Agonist, Is Effective in Improving Glycemic Control in Rats. Mol Pharmacol. 2021 Apr;99(4):286-293. |
| 保存条件: |
-80°C 6个月;-20°C 1个月 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.627 ml |
8.133 ml |
16.266 ml |
| 5 mM |
0.325 ml |
1.627 ml |
3.253 ml |
| 10 mM |
0.163 ml |
0.813 ml |
1.627 ml |
| 50 mM |
0.033 ml |
0.163 ml |
0.325 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |